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Introduction
Hypoxemia is a common clinical manifestation in
patients with liver cirrhosis. It may result from the
common cardiopulmonary diseases such as pneu-
monia, chronic obstructive pulmonary disease, con-
gestive heart failure and pulmonary edema. A rela-
tionship between cirrhotic liver and lung was first
described by Fluckiger1 in 1884 based on the
observation of a woman with cirrhosis, cyanosis and
clubbed digits. Several authors have since confirmed
this finding. In 1977, Kennedy and Knudson coined
the term “hepatopulmonary syndrome” to describe
this entity.2 This article reviews the clinical features
as well as the current understanding of the pathogen-
esis and clinical management of hepatopulmonary
syndrome.
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Hepatopulmonary syndrome is defined as the clinical triad of advanced liver disease, arterial deoxygenation and
intrapulmonary vascular dilatation. Its pathogenesis is not completely understood. Excessive pulmonary nitric oxide
production seems to be one of the factors that contribute to the intrapulmonary vascular dilatation. Other mediators
such as endothelin-1 and the heme oxygenase-1/carbon monoxide system have recently been found to be important
contributors. The major clinical manifestations are arterial hypoxemia, clubbed fingers and spider nevi. Orthodeoxia
is the characteristic clinical feature. Contrast-enhanced echocardiography is the preferred screening test.
99mTechnetium macroaggregated albumin (Tc-99m MAA) lung perfusion scan can further specify the diagnosis of
hepatopulmonary syndrome and quantify the magnitude of shunting. No clearly effective medical treatments have
been found. Although liver transplantation seems feasible to reverse this situation, it is associated with increased
postoperative morbidity and mortality. A preoperative arterial oxygen tension of 50 mmHg or less and Tc-99m MAA
shunt fractions of 20% or more are strong predictors of postoperative mortality that can be used to stratify patients
with better outcome. [J Chin Med Assoc 2005;68(11):500–505]
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Definition and Demographics
Hepatopulmonary syndrome (HPS) is characterized
by the triad of advanced liver disease, arterial hypoxemia
(arterial oxygen tension, PaO2 < 70 mmHg or alveolar-
arterial oxygen gradient > 20 mmHg at room air), and
intrapulmonary vascular dilatation.3–5 The prevalence
in the setting of cirrhosis ranges from 4% to 17%.6–8
The correlation between the severity of liver disease
and the existence of HPS remains controversial. One
prevailing concept is that the development of intra-
pulmonary vascular dilatation is related to the pro-
gression of liver dysfunction and correlates with sys-
temic vasodilatation and hyperdynamic circulation.9
In a prospective study, Vachiery et al10 suggested that
cirrhotic patients with HPS were characterized by a
higher Child-Pugh’s score and a higher hepatic venous
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pressure gradient. However, other studies did not
support this finding.11,12 There may be factors other
than the severity of liver disease that are important for
the development of HPS.
Pathogenesis
The exact pathogenesis of HPS is not completely
understood. Common bile duct ligation (CBDL) in rat
is the only recognized model for the study of HPS.13
It is interesting to note that in the animal model of
partial portal vein ligation (a model of portal hyperten-
sion but without cirrhosis), in which the rats develop
a similar degree of portal hypertension and hyperdyna-
mic circulation as CBDL rats, there is no detectable al-
teration of the pulmonary vasculature.14–16 Therefore, it
is possible that both hepatic injury and portal hyper-
tension are required for the development of HPS.
Castro and Krowka5 proposed that an imbalance
between vasoconstrictors and vasodilators in the pul-
monary vasculature contributed to the pathogenesis
of HPS. The most extensively investigated vasodilator
is nitric oxide (NO). Increased levels of exhaled nitrite
and nitrate, the metabolites of NO, are found in
patients with HPS; levels return to normal after liver
transplantation, with normalization of oxygen
saturation.17 In rats that develop HPS, the level of
endothelial NO synthase (eNOS) protein is increased
in the region of pulmonary small alveolar vessels, and
there is an increase in basal NOS activity. An NO-
mediated decreased response to vasoconstrictors in
the intralobar pulmonary arteries has also been
observed.14 Moreover, there is a positive correlation
between the extent of the increase in pulmonary eNOS
expression and the severity of gas exchange
abnormalities in HPS.14 Even though no significant
change in the level of inducible NO synthase (iNOS)
has been found, there might be a slight, difficult-to-
detect, increase in iNOS level.14 The role of iNOS in
HPS cannot be completely ruled out.18
In addition to NO, other vasoactive substances
have also been suggested to play a role in the
development of HPS. Increased hepatic expression
and plasma levels of endothelin-1 (ET-1) have been
observed in both experimental and human cirrhosis.19–21
Luo et al15 reported that increased ET-1 production
correlated with intrapulmonary molecular and gas
exchange abnormalities, and suggested that ET-1 may
contribute to the pathogenesis of HPS. Thereafter,
the same group of investigators also found increased
endothelin B (ETB) receptor expression in the
pulmonary vasculature from cirrhotic animals.16 It is
known that ET-1 may exert an autocrine vasodilatory
effect by increasing eNOS activity and subsequent NO
production via the ETB receptors on vascular endothe-
lial cells.22,23 Accordingly, Luo et al15 suggested that,
in response to the increased circulating ET-1 level in
cirrhosis, an increase in pulmonary vascular ETB
receptors may result in increased eNOS activity and
NO production, with subsequent intrapulmonary va-
sodilatation. The factors that contribute to increased
ETB receptor expression in pulmonary vasculature in
cirrhotics have not been completely established.
Hyperdynamic circulation-related increase in pulmo-
nary blood flow with a flow-mediated alteration in
vascular ETB receptor expression may play a role.
24,25
Other factors such as increased cytokine production,
particularly of interleukin-1`, and hypoxia that are
known to alter in cirrhosis may also modulate
intrapulmonary ETB receptor expression.
26,27
Carbon monoxide (CO) is another vasoactive sub-
stance that has recently been evaluated for its role in the
pathogenesis of HPS.28 CO can cause vasodilatation
by the cyclic guanosine monophosphate (cGMP)
independent pathway, possibly by directly activating
KCa channels.
29 CO is generated during the degrada-
tion of heme by heme oxygenase (HO), which has
constitutive and inducible isoforms.29 HO-1 is an
inducible protein that is expressed in a number of cell
types in the lung, most notably alveolar, bronchial
epithelium and inflammatory cells, including macro-
phages.29 Increased NO production in cirrhosis has
been shown to induce upregulation of intrapulmonary
HO-1 expression, which may be involved in the
pathogenesis of HPS.30 Zhang et al31 reported that
increased CO production induced by pulmonary HO-
1 overexpression in cirrhotic rats may contribute to the
progression of HPS. They also suggested that the
increase in pulmonary HO-1 protein may be caused by
the accumulation of intravascular macrophages in the
early stage after bile duct ligation when cirrhosis and
hemodynamic changes have not completely devel-
oped.31 Thereafter, increased CO production can be
observed with the development of HPS to worsen gas
exchange. However, the mechanism of macrophage
accumulation in the pulmonary vasculature is not
understood. Increased circulating tumor necrosis factor
_ may be an important triggering factor.31,32
Clinical Manifestations
Since intrapulmonary vascular dilatation leads to
ventilation-perfusion mismatch, the major clinical
manifestation of HPS is impaired oxygenation, which
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varies from a mild increase in the alveolar-arterial
oxygen gradient to severe arterial hypoxemia. As the
vascular abnormalities predominate in the middle to
lower lung fields,33 gravitational effects may increase
the blood flow to worsen the ventilation-perfusion
mismatch and, finally, result in a deterioration in
arterial oxygenation when in the upright position.34
Orthodeoxia, defined as arterial deoxygenation
accentuated in the upright position versus the supine
position, is a characteristic feature of HPS. A cutoff
value for orthodeoxia is defined by a PaO2 decrease of
5% or more, or 4 mmHg or more from the supine to
upright position.34 Its reported prevalence ranges from
20% to 80% in patients with HPS.12,35 Krowka and
Cortese36 found that the mean drop in PaO2 was 12
mmHg when patients stood from the supine position.
Clubbed fingers are common, and the presence of
spider nevi has been suggested as one of the most
sensitive clinical markers. In cirrhotic patients with
portal hypertension, spider nevi, clubbed fingers and
hypoxemia are highly suggestive of HPS.
Diagnosis
Several causes other than HPS may be involved in
cirrhosis presenting with hypoxemia, such as intrinsic
cardiopulmonary abnormalities, pulmonary atelectasis,
pneumonia, ascites, pulmonary edema or hepatic
hydrothorax. In cirrhotic patients with clinical
symptoms and arterial blood gas compatible with
hypoxemia, a chest film must first be taken to rule out
reversible conditions. Pulmonary function test should
be performed to rule out the common intrinsic pul-
monary disorders such as chronic obstructive pul-
monary disease. HPS should be suspected in patients
who have persistent hypoxia after a normal chest film
or after optimal treatment of the underlying conditions.
Contrast enhanced echocardiography is the pre-
ferred screening test for HPS.4,5 It uses agitated sa-
line or indocyanine green to produce microbubbles
at least 15 μm in diameter that are then injected
intravenously. Under normal circumstances, these
microbubbles are trapped in the pulmonary
microvasculature and then absorbed. In patients with
intracardiac or intrapulmonary shunting, these
microbubbles are seen in the left heart. Differentiation
between intracardiac and intrapulmonary shunting is
based on the timing of when these bubbles are found
in the left heart. In intracardiac right-to-left shunts,
these bubbles appear in the left heart in 3 heartbeats
after they appear in the right heart. In intrapulmonary
shunts, these bubbles appear in 4–6 heartbeats.
A recent study by Vedrinne et al37 revealed that
transesophageal echocardiography is more sensitive
than transthoracic echocardiography in demonstrating
intrapulmonary shunting. However, there are several
shortcomings of contrast enhanced echocardiography.
First, it cannot quantify the shunting. Second, it
cannot differentiate between intrapulmonary vascular
dilatation and direct arteriovenous communication.
Third, even though contrast echocardiography is highly
sensitive for HPS, it lacks specificity. A proportion of
cirrhotic patients with positive results on contrast
echocardiography have normal arterial blood gas and
do not fulfill the diagnostic criteria for HPS.8,38 Lastly,
in patients with concomitant intrinsic lung diseases,
the contribution of HPS to arterial desaturation cannot
be defined by contrast echocardiography.
In order to overcome the disadvantages of con-
trast echocardiography, the role of 99mtechnetium
macroaggregated albumin (Tc-99m MAA) lung
perfusion scan in diagnosing HPS was assessed. The
albumin macroaggregates are more than 20 μm in
diameter. Under normal circumstances, they are
entrapped in the pulmonary vasculature. In patients
with intracardiac or intrapulmonary shunts, these
albumin macroaggregates can escape the pulmonary
vasculature and be taken up by other organs. In
normal healthy patients, less than 5% of isotope can
be quantified in the brain. In HPS patients, the
fraction is more than 6%. In a cohort study, Tc-99m
MAA lung perfusion scan identified all cirrhotic
patients with HPS who presented with moderate to
severe hypoxemia, and yielded negative results in
those without HPS and in all non-cirrhotic hypoxic
patients with intrinsic lung disease.11 Accordingly,
Tc-99m MAA scan may be useful for the diagnosis of
HPS. In cirrhotic patients with concomitant intrinsic
pulmonary disorders, the fraction of Tc-99m MAA
scan can define the significance of the HPS in clinical
hypoxemia. That study also showed an inverse
correlation between the magnitude of the shunt
fraction and arterial oxygen saturation. The major
disadvantage of Tc-99m MAA scan is that it cannot
differentiate intracardiac from intrapulmonary
shunting. The shunt fraction of Tc-99m MAA scan
also does not correlate with the response of PaO2
after 100% oxygen is supplied.
Pulmonary angiography is an invasive procedure
that can show the appearance of the pulmonary
vasculature. A pulmonary arteriography study in
patients with HPS revealed 2 vascular patterns,36 the
type I or diffuse pattern and the type II or focal
pattern. The minimal diffuse type I pattern is
characterized by the presence of normal vessels or
Advances in hepatopulmonary syndrome
J Chin Med Assoc • November 2005 • Vol 68 • No 11 503
finely diffuse spidery vascular abnormalities. The
advanced type I pattern is characterized by a dif-
fuse spongy or blotchy appearance. The type II pat-
tern is a less frequent finding. Patients with advanced
type I or type II patterns show a poor response to 100%
oxygen. Due to the focal involvement of the pulmonary
vasculature and poor treatment response, patients
with a type II pattern should be considered for
embolization therapy.5 Pulmonary angiography
should, because of its invasiveness, only be reserved
for patients with HPS who respond poorly to 100% in-
spired oxygen and in whom vascular embolotherapy
can be performed at the same time to obliterate the
arteriovenous communications.39
Treatment and Prognosis
As the major clinical manifestation of HPS is arterial
hypoxemia, supplying oxygen is the first line of therapy.
Similar to oxygen therapy in patients with chronic
obstructive pulmonary disease, long-term oxygen
supply prolongs survival in patients with HPS. In pa-
tients with poor response to 100% oxygen, pulmonary
angiography with embolization therapy is an alternative.
Several medical treatments including almitrine
bismesylate, indomethacin, tamoxifen, somatostatin
analogues, sympathomimetics, `-blockers, methylene
blue and plasma exchange have been used in the
treatment of HPS with disappointing results.5,12,40 In
a retrospective analysis in 22 patients with HPS, the
mortality rate was approximately 41% after a mean
follow-up of 2.5 years.12 A prospective study on the
prognostic significance of HPS showed that HPS is an
independent predictor of survival, and mortality
correlates with HPS severity.41 As the presence of HPS
independently worsens the prognosis of cirrhotic
patients, its presence should influence clinical man-
agement. If patients are on the waiting list for liver
transplantation, the presence of HPS should be
combined with the MELD (model for end-stage liver
disease) score to accelerate the process for liver
transplantation.
A retrospective study by Krowka et al39 reported an
improvement or normalization of hypoxemia in about
80% of patients after liver transplantation. A prospective
study by Battaglia et al42 also demonstrated resolution
of intrapulmonary shunting in patients with HPS after
liver transplantation. It is thus considered that HPS
may be reversed after liver transplantation. The
pulmonary vascular changes after successful
transplantation show a slow remodeling process that
may take a long time for symptom relief. It has been
found that the lower the preoperative PaO2, the longer
the time to decrease the alveolar-arterial pressure
gradient and to improve arterial oxygenation.43
However, retrospective data show that there is a
higher mortality rate after liver transplantation in
patients with HPS than in those without HPS.44
Unique postoperative complications in patients with
HPS have been described, which include pulmonary
hypertension,45,46 embolic cerebral hemorrhage47 and
postoperative deterioration in oxygenation. These
unique postoperative complications, along with delayed
resolution of hypoxemia, are implicated in the higher
mortality rate. For patients with severe preoperative
hypoxemia (PaO2 ) 50 mmHg) and significant
intrapulmonary shunting (Tc-99m MAA shunt frac-
tion * 20%), the mortality rate may increase further
after liver transplantation.39,48
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